Exicure to issue shares worth $1M to settle milestone payment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
August 3, 2026 9:24 AM EDTWILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (Exicure or the Company) today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. (GPCR Therapeutics) during August 2026 in settlement of a $1.0 million clinical milestone payment obligation under the parties License and Collaboration Agreement.
The milestone payment was triggered by the completion of the Phase 2 clinical trial of Burixafor (GPC-100), including the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026.
... More